HC Wainwright & Co. Maintains Buy on Metagenomi, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Metagenomi (NASDAQ:MGX) but lowered the price target from $10 to $7, indicating a more cautious outlook on the stock's potential upside.
August 21, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Metagenomi but lowered the price target from $10 to $7, suggesting a more cautious outlook on the stock's potential upside.
The maintenance of a Buy rating suggests continued confidence in Metagenomi's prospects, but the lowered price target indicates a tempered expectation of its short-term performance. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100